KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.96

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.

Kristina Lindemann, Dominique Berton, Jalid Sehouli, René DePont Christensen, Sevilay Altintas, Anja Ør Knudsen, Pierre-Etienne Heudel, Beyhan Ataseven, Ignace Vergote, Gabriel Lindahl, Coriolan Lebreton, Fabienne Schochter, Annika Auranen, Philippe Follana, Kristine Madsen, Frédéric Selle, Karen Stampe Petersson, Florence Joly, Elena Ioana Braicu, Mansoor Raza Mirza

Gynecol Oncol 199 79-87

PMID40592025
PMCID-
DOI10.1016/j.ygyno.2025.06.008
发表日期2025-07-01
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:The record is explicitly identified as a Phase II randomized controlled trial, not Phase III. The keywords mention 'Phase 3 placebo-controlled trial', but this is inconsistent with the primary metadata (title, publication types) and the study's own conclusion, which recommends against Phase III evaluation.
摘要

摘要

OBJECTIVE: Patients with advanced or recurrent endometrial cancer (EC) have poor prognosis despite treatment with combination chemotherapy. This study explored the preliminary efficacy of the potent oral tyrosine kinase inhibitor nintedanib (N), in addition to chemotherapy. METHODS: Patients with histologically confirmed stage FIGO 2009 stage IIIC2-IV or recurrent EC were randomized 1:1 to receive N 200 mg or placebo (P), twice daily days 2-21 during chemotherapy (six cycles of Carboplatin (AUC5) and paclitaxel (175 mg/m2) every 21 days (TC)) and in maintenance until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was progression-free survival (PFS). RESULTS: Between November 30th, 2016, and January 11th, 2019 146 participants (mean age 66.1 years) were randomized and had received at least one dose of N/P: 72 patients to the N + TC arm and 74 to the P + TC arm. After median follow-up time of 43.9 months (95 % CI: 41.8-45.6), median PFS was 8.2 63 months (95 % CI: 5.77-10.27) in the N + TC arm and 7.1 months (95 % CI: 5.40-9.10) in the P + TC arm (HR 0.99, 95 % CI: 0.69-1.43, p = 0.992). There was no difference in median overall survival (OS) (HR 0.82; 96 % CI: 0.54-1.25, p = 0.365). Treatment-emergent grade 3-4 adverse events were higher in N + TC vs P + TC arm, in particular increase in blood alanine aminotransferase (18.1 % vs 4.1 %) and diarrhea (10.8 % and 1.3 %). CONCLUSIONS: Addition of nintedanib to chemotherapy did not improve PFS nor OS. Phase III evaluation of this regimen is not recommended.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。